The US Supreme Court will soon decide a case challenging the US Food and Drug Administration’s (FDA’s) approval of mifepristone. Author Holly Fernandez Lynch, JD, MBE, University of Pennsylvania, joins JAMA Executive Editor Gregory Curfman, MD, to discuss the science and politics surrounding this significant case.

Related Content:

• The FDA in the Crosshairs—Science, Politics, and Abortion
• Provision of Medications for Self-Managed Abortion Before and After the Dobbs v Jackson Women’s Health Organization Decision
• Understanding the Impacts of the Supreme Court Case FDA v Alliance for Hippocratic Medicine